• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Poo transplant effective treatment for chronic bowel condition

Bioengineer by Bioengineer
January 15, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Poo transplant or “Faecal microbiota transplantation” (FMT) can successfully treat patients with ulcerative colitis, new research from the University of Adelaide shows.

The randomised, double-blind study – published in the journal JAMA – was a collaboration between the University of Adelaide, South Australian Health and Medical Research Institute (SAHMRI), CSIRO and CALHN (SA Health).

It involved 73 adults with mild to moderate active ulcerative colitis, an inflammatory bowel disease which effects the lining of the large intestine and rectum causing symptoms including pain, bloody stools and an increased risk of colon cancer.

Patients received either pooled donor FMT that had been anaerobically processed or their own stool as placebo via colonoscopy followed by two enemas.

Researchers found a short duration of low intensity FMT using anaerobically (in an oxygen-free environment) prepared pooled donor FMT could induce remission in ulcerative colitis, with a 32% rate of remission compared to 9% with placebo. This is a similar treatment result to the best currently available therapies.

Many of the currently available therapies for ulcerative colitis improve the disease by suppressing the immune system which can lead to potential side effects like infection or malignancy.

“The most important difference in this trial compared to previous studies is the use of anaerobic (oxygen-free) stool processing,” says study leader Dr Sam Costello, Gastroentrologist, The Queen Elizabeth Hospital and Lecturer, University of Adelaide’s Medical School.

“Many gut bacteria die with exposure to oxygen and we know that with anaerobic stool processing a large number of donor bacteria survive so that they can be administered to the patient.

“We believe that this may be the reason that we had a good therapeutic effect with only a small number of treatments.”

An agreement has already been reached with UK company Microbiotica to commercialise the development of a microbial therapeutic from the study.

“Our long-term aim is to develop rationally designed microbial therapies that can replace FMT,” says Dr Costello.

“These will have bacteria in a pill that can carry out the therapeutic effect without the need to take whole faeces.

“This is obviously a better and less smelly option.”

Further studies will investigate whether FMT can maintain remission in ulcerative colitis.

###

Media Contact
Sam Costello
[email protected]
61-041-331-1793

Related Journal Article

http://doi.org/10.1001/jama.2018.20046
http://dx.doi.org/10.1001/jama.2018.20046

Tags: Internal MedicineMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Unraveling EMT’s Role in Colorectal Cancer Spread

August 2, 2025
Gut γδ T17 Cells Drive Brain Inflammation via STING

Gut γδ T17 Cells Drive Brain Inflammation via STING

August 2, 2025

Agent-Based Framework for Assessing Environmental Exposures

August 2, 2025

MARCO Drives Myeloid Suppressor Cell Differentiation, Immunity

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    39 shares
    Share 16 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unraveling EMT’s Role in Colorectal Cancer Spread

Gut γδ T17 Cells Drive Brain Inflammation via STING

Agent-Based Framework for Assessing Environmental Exposures

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.